Exelixis, Inc. (EXEL) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $52.33 (-1.28%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 4, 2026 | Etzer Darout | Barclays | $44.00 | -15.9% |
| Feb 2, 2026 | Sean Laaman | Morgan Stanley | $49.00 | -6.4% |
| Jan 8, 2026 | Robert Burns | H.C. Wainwright | $52.00 | -0.6% |
| Nov 5, 2025 | Robert Burns | H.C. Wainwright | $49.00 | -6.4% |
| Nov 5, 2025 | Stephen Willey | Stifel Nicolaus | $43.00 | -17.8% |
| Nov 5, 2025 | Etzer Darout | Barclays | $41.00 | -21.7% |
| Nov 5, 2025 | Silvan Tuerkcan | Oppenheimer | $36.00 | -31.2% |
| Oct 21, 2025 | Derek Archila | Wells Fargo | $30.00 | -42.7% |
| Aug 12, 2025 | Robert Burns | H.C. Wainwright | $46.00 | -12.1% |
| Jul 15, 2025 | Asthika Goonewardene | Truist Financial | $56.00 | +7.0% |
| Jul 11, 2025 | Ashwani Verma | UBS | $43.00 | -17.8% |
| May 15, 2025 | Michael Schmidt | Guggenheim | $45.00 | -14.0% |
| May 14, 2025 | Sean Laaman | Morgan Stanley | $47.00 | -10.2% |
| Jan 27, 2025 | Silvan Tuerkcan | JMP Securities | $41.00 | -21.7% |
| Jan 10, 2025 | Robert Burns | H.C. Wainwright | $40.00 | -23.6% |
| Jan 7, 2025 | Michael Schmidt | Guggenheim | $42.00 | -19.7% |
| Oct 30, 2024 | Etzer Darout | BMO Capital | $36.00 | -31.2% |
| Oct 30, 2024 | Asthika Goonewardene | Truist Financial | $38.00 | -27.4% |
| Oct 30, 2024 | Joseph Catanzaro | Piper Sandler | $36.00 | -31.2% |
| Oct 30, 2024 | David Lebowitz | Citigroup | $38.00 | -27.4% |
Top Analysts Covering EXEL
EXEL vs Sector & Market
| Metric | EXEL | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.65 | 2.24 | 2.40 |
| Analyst Count | 17 | 8 | 19 |
| Target Upside | -10.9% | +11475.1% | +17.1% |
| P/E Ratio | 17.86 | 3.89 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2027-01-02 | $2.51B | $2.59B | $2.66B | 15 |
| 2027-04-02 | $684M | $699M | $715M | 9 |
| 2027-07-02 | $711M | $726M | $742M | 5 |
| 2027-10-02 | $750M | $766M | $783M | 5 |
| 2028-01-02 | $778M | $795M | $813M | 6 |
| 2028-04-02 | $824M | $842M | $861M | 9 |
| 2028-07-02 | $848M | $867M | $886M | 4 |
| 2028-10-02 | $879M | $899M | $919M | 4 |
| 2029-01-02 | $918M | $938M | $959M | 8 |
| 2030-01-02 | $3.15B | $3.40B | $3.56B | 7 |
| 2031-01-02 | $2.94B | $3.17B | $3.32B | 11 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2027-01-02 | $3.13 | $3.31 | $3.57 | 12 |
| 2027-04-02 | $0.88 | $0.91 | $0.93 | 3 |
| 2027-07-02 | $0.92 | $0.94 | $0.97 | 5 |
| 2027-10-02 | $0.98 | $1.00 | $1.03 | 3 |
| 2028-01-02 | $1.01 | $1.04 | $1.07 | 6 |
| 2028-04-02 | $1.01 | $1.04 | $1.07 | 4 |
| 2028-07-02 | $1.04 | $1.07 | $1.10 | 6 |
| 2028-10-02 | $1.08 | $1.11 | $1.14 | 4 |
| 2029-01-02 | $1.13 | $1.16 | $1.19 | 5 |
| 2030-01-02 | $4.98 | $5.49 | $5.83 | 5 |
| 2031-01-02 | $4.90 | $5.39 | $5.73 | 6 |
Frequently Asked Questions
What is the analyst consensus for EXEL?
The consensus among 17 analysts covering Exelixis, Inc. (EXEL) is Hold with an average price target of $44.11.
What is the highest price target for EXEL?
The highest price target for EXEL is $56.00, set by Asthika Goonewardene at Truist Financial on 2025-07-15.
What is the lowest price target for EXEL?
The lowest price target for EXEL is $18.00, set by Chris Shibutani at Goldman Sachs on 2024-10-16.
How many analysts cover EXEL?
17 analysts have issued ratings for Exelixis, Inc. in the past 12 months.
Is EXEL a buy or sell right now?
Based on 17 analyst ratings, EXEL has a consensus rating of Hold (2.65/5) with a -10.9% upside to the consensus target of $44.11.
What are the earnings estimates for EXEL?
Analysts estimate EXEL will report EPS of $3.31 for the period ending 2027-01-02, with revenue estimated at $2.59B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.